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Melatonin (N-acetyl-5-methoxy-triptamine) is the 
major product of the pineal gland; however, it has also 
been identified in a large number of extrapineal organs 
including the gastrointestinal tract, cornea, bone mar-
row, lymphocytes, etc. [1]. Melatonin has well-known 
anti-oxidative, oncostatic, and anti-aging properties 
and numerous experimental and clinical data have 
established its beneficial effects [2–4]. Melatonin ex-
erts some of its physiological effects in immune cells 
through two G-protein-coupled specific membrane 
receptors: MT1 (cAMP signalling pathway) and MT2 
(cGMP signalling pathway). There is now evidence 
that melatonin possesses important immunoenhanc-
ing properties, mostly underlined in immunodepressed 
situations [3], and it may counteract the immunosup-
pressive effect of corticotherapy. Melatonin promotes 
a Th1-mediated response (Th1 cells produce far more 
interferon g (IFN-g) and interleukin 2 (IL-2) than Th2 
cells), thereby activating inflammatory pathways. How-
ever, melatonin can also stimulate Th2 cells which pro-
duce far more IL-4 and IL-10 than do the Th1 cells. Th2 
cells stimulate antibody production via B lymphocytes 
and down regulate Th1 cells, and thus they may inhibit 
some Th1-mediated inflammatory responses [5–7]. 
Although melatonin is one of the least toxic sub-
stances known, its pharmacological effect on some 
autoimmune diseases such as rheumatoid arthritis 
and Crohn’s disease at this point is controversial [8]. In 
1997, Hong et al. [9] reported a patient who developed 
autoimmune hepatitis after beginning melatonin ther-
apy for the treatment of insomnia. Recently, Fourman 
et al. [10] reported a case of autoimmune hepatitis that 
developed in a 50-year-old man after starting ramelte-
on, a melatonin agonist, for insomnia.
Here we present a patient with primary sclerosing 
cholangitis (PSC) with features of autoimmune hepatitis 
(AIH) and associated with ulcerative colitis, who devel-
oped a severe elevation of liver enzymes following the 
use of melatonin in two separate courses. 
The patient was a 25-year-old female with a history 
of autoimmune hepatitis diagnosed at the age 23 years 
in a local hospital and treated with corticosteroids and 
azathioprine for 2 years. She denied taking any other 
medications as well as supplements for depression in-
cluding St John’s wort, which has been known to cause 
serious interactions with some drugs. Because she ex-
perienced no response to the therapy she was referred 
to our hospital. On admission, she was asymptomatic. 
There was no history of risk factors for liver disease 
such as malnutrition, prior blood transfusion or surgi-
cal procedures, alcohol or drug abuse, or contact with 
high-risk individuals. Her family history was noncontrib-
utory, and her physical examination was unremarkable. 
Gynaecological and neurological examination also re-
vealed no abnormalities. Laboratory tests are presented 
in Table I. The immunological profile was positive for 
anti-nuclear antibody and anti-smooth muscle antibody 
at titres of 1 : 160 and 1 : 320, respectively, and se-
ronegative for anti-mitochondrial antibody, anti-liver/
kidney microsomal antibody, and perinuclear anti-neu-
trophil cytoplasmic antibody (done by indirect immu-
nofluorescence). Results of serologic tests for hepatitis 
A, B, and C viruses and for antibodies to cytomegal-
ovirus (CMV) and Epstein-Barr viruses were negative. 
The result of polymerase chain reaction (PCR) testing 
for HCV-RNA was also negative. Normal values were ob-
tained for the following parameters: α1-antitrypsin, ce-
ruloplasmin, ferritin, albumin, triglycerides, and glucose. 
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Magnetic resonance cholangiopancreatography (MRCP) 
showed focally narrowed common bile duct indicating 
PSC. Colonoscopy revealed evidence of active ulcerative 
colitis (UC) with diffuse mucosal inflammation and ul-
cerations in the colon from the rectum to the proximal 
colon (pancolitis). Microscopic examination of biopsy 
specimens showed mucosal ulcerations, infiltration of 
lamina propria with inflammatory cells and crypt ab-
scesses. 
The liver biopsy revealed histological findings that re-
sembled those found in the initial biopsy performed two 
years earlier in a local hospital. The findings included 
hepatocyte ballooning degeneration, mild inflammatory 
infiltration of portal zones primarily of lymphocytes with 
focal interface hepatitis, and mild portal fibrosis, but 
lymphocytes surrounding some of bile ducts were noted 
as a new feature. The patient was diagnosed with PSC 
with features of AIH associated with UC. Treatment was 
switched to mycophenolate mofetil (Celcept) 1000 mg 
daily, mesalazine 3 g daily and ursodeoxycholic acid 
(UDCA) 15 mg/kg daily. However, because she did 
not tolerate mesalazine, she was left with mycophe-
nolate mofetil and UDCA only. The patient was then 
discharged and was assessed at 4- to 6-week intervals 
in the outpatient clinic. Figure 1 presents biochemical 
events in relation to therapy. The patient’s aminotrans-
ferase levels decreased gradually to normal within two 
months, whereas the cholestatic component remained 
abnormal. Approximately 4 months later, her serum liv-
er enzyme levels abruptly rose. She was then admitted 
again. She remained asymptomatic. Complete blood 
count, serum bilirubin level, and prothrombin time were 
all normal. Serum testing for hepatitis B virus (HBV), 
hepatitis C virus (HCV), and CMV viruses were negative. 
The macroscopic appearances of colonoscopy showed 
irregular mucosal surface without ulceration. The pa-
tient’s drug history was revisited at that point, and we 
discovered that approximately 3 months before admis-
sion she had started to take melatonin (5 mg) at bed-
time for insomnia. We considered whether melatonin 
could be a potential cause of marked elevation of se-
rum aminotransferase levels. The patient then stopped 
consuming melatonin while mycophenolate mofetil 
and UDCA were continually administered at unchanged 
doses. Her serum aminotransferase levels gradually de-
clined and returned to pre-melatonin treatment levels 
during two months; however, cholestatic enzyme levels 
did not change significantly. 
Following approximately seven months of success-
ful management the patient again started by herself 
to take melatonin 5 mg at bedtime to improve sleep 
propensity. After about three weeks of melatonin use, 
a routine liver enzymes test revealed a marked eleva-
tion of serum alanine aminotransferase (ALT) and as-
partate aminotransferase (AST) levels from values near 
normal to approximately 10× upper limit of normal 
(ULN) and 8× ULN, respectively. Alkaline phosphatase 
(ALP) and g-glutamyl transpeptidase (GGT) levels also 
rose; however, they were significantly elevated prior to 
melatonin administration (Figure 1). The patient was 
strongly recommended to withdraw melatonin and 
avoid it in the future. The existing daily doses of my-
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 ALT – alanine aminotransferase (normal, < 40 UI/l)
 AST – aspartate aminotransferase (normal, < 40 UI/l)
 ALP – alkaline phosphatase (normal, < 120 UI/l)
 GGT – g-glutamyl transpeptidase (normal, < 75 UI/l)
MT – melatonin 5 mg/day
Figure 1. Biochemical events in relation to ther-
apy
Table I. Clinical and laboratory findings at the time  
of admission
Parameter Results
Sex Female
Age [year] 25
BMI [kg/m2] 24.3
Glucose (normal range: 3.9–5.5 mmol/l) 5.4
ALT (normal< 40 UI/l) 200
AST (normal < 40 UI/l) 129
ALP (normal < 120 UI/l) 309
GGT (normal < 55 IU/l) 258
Bilirubin (normal range: 0.2–1 mg/dl) 1.1
Cholesterol (normal range: 150–200 mg/dl) 258
IgA (normal range: 0.70–4.0 g/l) 1.23
IgG (normal range: 7.0–16.0 g/l) 17.39
IgM (normal range: 0.40–2.30 g/l) 3.07
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cophenolate motefil and UDCA were maintained. The 
aminotransferase levels decreased significantly 1 month 
after melatonin withdrawal, and they were minimal-
ly increased above or within the normal range during 
18 months of follow-up. Currently, the AIH component of 
the AIH/PSC overlap is being successfully controlled with 
mycophenolate motefil, but an MRC, which was conduct-
ed as part of PSC follow-up, revealed evidence of extra- 
and intrahepatic duct abnormalities consistent with PSC. 
In our patient, the temporal association between 
administration of melatonin and elevation in liver en-
zymes observed over the two separate courses of this 
drug strongly suggest that melatonin caused the ex-
acerbation of biochemical flares. The flare regression 
to melatonin withdrawal additionally supports this 
suggestion. Melatonin is not known to be hepatotoxic; 
therefore, in our patient the increase in liver enzyme 
levels during melatonin therapy is unlikely to have rep-
resented hepatotoxicity, but it is consistent with an ex-
acerbation of the underlying autoimmune liver disease. 
There are only a few published cases of the tem-
poral relationship between melatonin use and the de-
velopment or aggravation of autoimmune disorders. 
To date, there is only one case report [8] in a patient 
who developed autoimmune hepatitis after beginning 
melatonin therapy for the treatment of insomnia. In 
addition, Maestroni et al. [11] and Calvo et al. [12] 
postulated the disease-promoting role of melatonin in 
rheumatoid arthritis and Crohn’s disease, respectively, 
but no such cases have been reported. Our report is 
clinically important because many people use melatonin 
to help improve their sleep. 
Because of the very few side effects, melatonin is 
available without prescription in some European coun-
tries, while in the United States melatonin is considered 
a dietary supplement. While there are many situations 
in which melatonin has not been shown to aggravate 
autoimmune diseases, we suggest that caution should 
be exercised before initiating melatonin therapy in pa-
tients who potentially have autoimmune liver disease. 
Even if melatonin can be used in those patients, one 
should remember this side effect, especially after re-
peated doses.
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